Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346338 | 0.84 | — | — | |
| Methyl Alcohol SCHEMBL8740635 | 0.82 | CRBN (0.39) | CRBN | |
| Methacrylic Acid SCHEMBL1146682 | 0.77 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Glycine SCHEMBL8303383 | 0.77 | GLRA1 (0.43) | CRBN | |
| SCHEMBL15080651 | 0.76 | CRBN (0.35) | CRBN | |
| Pyruvate SCHEMBL21145028 | 0.71 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Oxalic Acid SCHEMBL216302 | 0.71 | FFAR3 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Acetic Acid SCHEMBL16244302 | 0.71 | FFAR3 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Oxalic Acid SCHEMBL1840973 | 0.71 | FFAR3 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Acetic Acid SCHEMBL19356582 | 0.71 | FFAR3 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567535-B1 | BIDENTATE C,P CHIRAL PHOSPHINE LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6984744-B2 | Phosphine ligands | HOFFMAN-LA ROCHE INC. (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1567535-A1 | BIDENTATE C,P CHIRAL PHOSPHINE LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050669-A1 | BIDENTATE C,P CHIRAL PHOSPHINE LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110975-A1 | 2-(2-phosphinoethyl)phospholanes and transition metal complexes with such ligands in asymmetric hydrogenation reactions; phospholone intermediates | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110975-A1 | 2-(2-phosphinoethyl)phospholanes and transition metal complexes with such ligands in asymmetric hydrogenation reactions; phospholone intermediates | CCRL2, LUC7L2, CDKL1 | CHRM2 2278/4885CHRM4 2479/4885CHRM5 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.